Shan Riku Sakakibara Sells 8,000 Shares of Billiontoone (NASDAQ:BLLN) Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Shan Riku Sakakibara sold 8,000 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $98.22, for a total transaction of $785,760.00. Following the sale, the insider owned 212,000 shares of the company’s stock, valued at $20,822,640. This represents a 3.64% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Billiontoone Stock Performance

Shares of NASDAQ BLLN traded down $3.13 during midday trading on Wednesday, reaching $99.26. 1,040,614 shares of the stock were exchanged, compared to its average volume of 694,048. The company has a 50 day simple moving average of $87.26 and a 200 day simple moving average of $88.18. The company has a quick ratio of 10.58, a current ratio of 10.92 and a debt-to-equity ratio of 0.18. Billiontoone, Inc. has a twelve month low of $61.96 and a twelve month high of $138.70.

Billiontoone (NASDAQ:BLLN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.33. The firm had revenue of $108.39 million for the quarter, compared to analyst estimates of $95.81 million. The firm’s quarterly revenue was up 83.8% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.39) EPS. As a group, sell-side analysts forecast that Billiontoone, Inc. will post 0.93 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BLLN has been the subject of a number of recent analyst reports. Wells Fargo & Company cut their price target on shares of Billiontoone from $110.00 to $90.00 and set an “equal weight” rating for the company in a report on Thursday, March 5th. BTIG Research cut their price target on shares of Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Guggenheim raised their price target on shares of Billiontoone from $100.00 to $120.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. Wall Street Zen raised shares of Billiontoone from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. Finally, Weiss Ratings cut shares of Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 5th. Six research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $125.29.

Hedge Funds Weigh In On Billiontoone

A number of hedge funds have recently made changes to their positions in the stock. Baillie Gifford & Co. purchased a new stake in Billiontoone during the fourth quarter worth about $103,786,000. Massachusetts Financial Services Co. MA purchased a new stake in Billiontoone during the fourth quarter worth about $13,373,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Billiontoone during the fourth quarter worth about $1,348,000. UBS Group AG purchased a new stake in Billiontoone during the fourth quarter worth about $2,586,000. Finally, Seven Grand Managers LLC purchased a new stake in Billiontoone during the fourth quarter worth about $2,046,000.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.